DrugPatentWatch Database Preview
Sandoz Inc Company Profile
» See Plans and Pricing
What is the competitive landscape for SANDOZ INC, and what generic alternatives to SANDOZ INC drugs are available?
SANDOZ INC has one hundred and thirty-five approved drugs.
There are three US patents protecting SANDOZ INC drugs. There are fourteen tentative approvals on SANDOZ INC drugs.
There is one patent family member on SANDOZ INC drugs in one country and two hundred and twenty-seven supplementary protection certificates in fifteen countries.
Summary for Sandoz Inc
| International Patents: | 1 |
| US Patents: | 3 |
| Tradenames: | 109 |
| Ingredients: | 106 |
| NDAs: | 135 |
| Patent Litigation for Sandoz Inc: | See patent lawsuits for Sandoz Inc |
| PTAB Cases with Sandoz Inc as petitioner: | See PTAB cases with Sandoz Inc as petitioner |
Drugs and US Patents for Sandoz Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz Inc | LATANOPROST | latanoprost | SOLUTION/DROPS;OPHTHALMIC | 091449-001 | Mar 22, 2011 | AT | RX | No | No | Start Trial | Start Trial | ||||
| Sandoz Inc | METHYLPREDNISOLONE ACETATE | methylprednisolone acetate | INJECTABLE;INJECTION | 040794-001 | Mar 5, 2009 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Sandoz Inc | BIMATOPROST | bimatoprost | SOLUTION/DROPS;TOPICAL | 202719-001 | Apr 19, 2016 | AT | RX | No | No | Start Trial | Start Trial | ||||
| Sandoz Inc | CIMETIDINE | cimetidine | TABLET;ORAL | 074250-002 | Jun 29, 1995 | DISCN | No | No | Start Trial | Start Trial | |||||
| Sandoz Inc | PHENYLEPHRINE HYDROCHLORIDE | phenylephrine hydrochloride | SOLUTION;INTRAVENOUS | 208905-002 | Jan 31, 2019 | AP1 | RX | No | No | Start Trial | Start Trial | ||||
| Sandoz Inc | KETOROLAC TROMETHAMINE | ketorolac tromethamine | SOLUTION/DROPS;OPHTHALMIC | 078721-001 | Nov 5, 2009 | DISCN | No | No | Start Trial | Start Trial | |||||
| Sandoz Inc | ANGIOMAX | bivalirudin | INJECTABLE;INTRAVENOUS | 020873-001 | Dec 15, 2000 | AP | RX | Yes | Yes | 7,582,727*PED | Start Trial | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sandoz Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sandoz Inc | BETOPTIC | betaxolol hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019270-001 | Aug 30, 1985 | 4,311,708 | Start Trial |
| Sandoz Inc | ANGIOMAX | bivalirudin | INJECTABLE;INTRAVENOUS | 020873-001 | Dec 15, 2000 | 5,196,404*PED | Start Trial |
| Sandoz Inc | BETOPTIC | betaxolol hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019270-001 | Aug 30, 1985 | 4,342,783 | Start Trial |
| Sandoz Inc | TIMOLOL MALEATE | timolol maleate | SOLUTION, GEL FORMING/DROPS;OPHTHALMIC | 020963-001 | Oct 21, 1998 | 6,174,524*PED | Start Trial |
| Sandoz Inc | TIMOLOL MALEATE | timolol maleate | SOLUTION, GEL FORMING/DROPS;OPHTHALMIC | 020963-002 | Oct 21, 1998 | 6,174,524*PED | Start Trial |
| Sandoz Inc | BETOPTIC | betaxolol hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019270-001 | Aug 30, 1985 | 4,252,984 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SANDOZ INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | For Injection | 250 mg/vial | ➤ Subscribe | 2009-09-01 |
International Patents for Sandoz Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2505836 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sandoz Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0521471 | C300125 | Netherlands | Start Trial | PRODUCT NAME: ROSUVASTATINUM, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET CALCIUMZOUT; REGISTRATION NO/DATE: RVG 26872 - RVG 26874 20021106 |
| 0503785 | CA 2011 00026 | Denmark | Start Trial | PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216 |
| 0656775 | 28/2000 | Austria | Start Trial | PRODUCT NAME: BUPROPION HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-23680 20000616; FIRST REGISTRATION: NL 24160 19991201 |
| 0720599 | 122014000088 | Germany | Start Trial | PRODUCT NAME: EZETIMIB ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON IN KOMBINATION MIT ATORVASTATIN ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, INSBESONDERE ATORVASTATIN ALS ATORVASTATINCALCIUMTRIHYDRAT; NAT. REGISTRATION NO/DATE: 90223.00.00 20141113; FIRST REGISTRATION: FRANKREICH CIS: 6 928 917 6 20140912 |
| 0600675 | 10C0036 | France | Start Trial | PRODUCT NAME: SILODOSIN; REGISTRATION NO/DATE IN FRANCE: EU/1/09/608/001 DU 20100129; REGISTRATION NO/DATE AT EEC: EU/1/09/608/001 DU 20100129 |
| 1381356 | 2014/004 | Ireland | Start Trial | PRODUCT NAME: TERIFLUNOMIDE, ITS STEREOISOMER AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/838/001-005 20130826 |
| 2316456 | CA 2017 00062 | Denmark | Start Trial | PRODUCT NAME: NALTREXON ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NALTREXONHYDROCHLORID, OG BUPROPION ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER BUPROPIONHYDROCHLORID; REG. NO/DATE: EU/1/14/988 20150330 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
